X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CAP-1002 consists of allogeneic cardiosphere-derived cells (CDCs), having potent immunomodulatory, antifibrotic and regenerative actions in dystrophinopathy and heart failure. It is under late stage clinical development for the treatment of Duchenne muscular dystrophy.
Lead Product(s): Allogeneic Cardiosphere-derived Cell
Therapeutic Area: Genetic Disease Product Name: CAP-1002
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2024
Details:
CAP-1002 consists of allogeneic cardiosphere-derived cells (CDCs), having potent immunomodulatory, antifibrotic and regenerative actions in dystrophinopathy and heart failure. It is under late stage clinical development for the treatment of Duchenne muscular dystrophy.
Lead Product(s): CAP-1002
Therapeutic Area: Genetic Disease Product Name: CAP-1002
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
The collaboration aims to support Capricor’s proprietary StealthX™ exosome-based multivalent vaccine (StealthX™ vaccine) for the prevention of SARS-CoV-2.
Lead Product(s): Exosome-based Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: StealthX
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 24, 2024
Details:
CAP-1002 consists of allogeneic cardiosphere-derived cells (CDCs), having potent immunomodulatory, antifibrotic and regenerative actions in dystrophinopathy and heart failure. It is under late stage clinical development for the treatment of Duchenne muscular dystrophy.
Lead Product(s): Allogeneic Cardiosphere-derived Cell
Therapeutic Area: Genetic Disease Product Name: CAP-1002
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
The Company intends to use the net proceeds from this offering on research and development related to its product candidates, including CAP-1002, an investigational allogeneic cardiosphere-derived cell therapy intended to treat Duchenne muscular dystrophy.
Lead Product(s): CAP-1002
Therapeutic Area: Genetic Disease Product Name: CAP-1002
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cantor Fitzgerald & Co.
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 29, 2023
Details:
CAP-1002 is an allogeneic cardiac-derived cell (CDCs) therapy that is in late-stage clinical development for treating DMD. CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy.
Lead Product(s): CAP-1002
Therapeutic Area: Genetic Disease Product Name: CAP-1002
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2023
Details:
CAP-1002 (Allogeneic Cardiosphere-Derived Cell Therapy) is an off-the-shelf CDCs that has been shown to exert potent immunomodulatory activity. It is being investigated for potential to modify the immune system’s activity for cellular regeneration for treament of DMD.
Lead Product(s): CAP-1002
Therapeutic Area: Genetic Disease Product Name: CAP-1002
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2023
Details:
CAP-1002 consists of allogeneic Allogeneic Cardiosphere-derived Cells, a type of progenitor cell, exert potent immuno-modulatory activity and is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration.
Lead Product(s): Allogeneic Cardiosphere-derived Cell
Therapeutic Area: Genetic Disease Product Name: CAP-1002
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Nippon Shinyaku
Deal Size: $101.0 million Upfront Cash: $12.0 million
Deal Type: Partnership February 16, 2023
Details:
CAP-1002 is an allogeneic “off-the-shelf” CDCs, a type of cardiac cell therapy that has been shown to exert potent immunomodulatory activity. It is being investigated for its potential to modify the immune system’s activity for cellular regeneration for the treament of DMD.
Lead Product(s): CAP-1002
Therapeutic Area: Genetic Disease Product Name: CAP-1002
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
CAP-1002 is an allogeneic cardiac-derived cell (CDCs) therapy that is in late-stage clinical development for treating DMD. CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy.
Lead Product(s): Allogeneic Cardiosphere-derived Cells
Therapeutic Area: Genetic Disease Product Name: CAP-1002
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
